Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:microbicide
|
| gptkbp:activeIngredient |
tenofovir
|
| gptkbp:administeredBy |
vaginal application
|
| gptkbp:concentration |
1%
|
| gptkbp:developer |
gptkb:Gilead_Sciences
|
| gptkbp:effect |
reduced HIV acquisition in clinical trials
reduced HSV-2 acquisition in clinical trials |
| gptkbp:form |
topical gel
|
| gptkbp:intendedUse |
HIV prevention
HSV-2 prevention |
| gptkbp:mechanismOfAction |
reverse transcriptase inhibition
|
| gptkbp:routeOfAdministration |
topical
|
| gptkbp:status |
gptkb:investigational_drug
|
| gptkbp:studiedIn |
gptkb:CAPRISA_004_trial
|
| gptkbp:studiedPopulation |
gptkb:women
|
| gptkbp:bfsParent |
gptkb:CAPRISA_004_microbicide_trial
|
| gptkbp:bfsLayer |
7
|
| http://www.w3.org/2000/01/rdf-schema#label |
1% tenofovir gel
|